Author:
Zhou Xikun,Qiu Ji,Wang Zhen,Huang Nongyu,Li Xiaolei,Li Qian,Zhang Yinbing,Zhao Chengjian,Luo Can,Zhang Nannan,Teng Xiu,Chen Zhongwen,Liu Xiao,Yu Xianlian,Wu Wenling,Wei Yu-quan,Li Jiong
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,General Medicine
Reference39 articles.
1. Allen TM (2002) Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2(10):750–763
2. Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W, Ruhl J, Howlader N, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Cronin K, Chen HS, Feuer EJ, Stinchcomb DG, Edwards BK (eds) (2009) SEER Cancer statistics review, 1975–2007. National Cancer Institute, Bethesda
3. Baluna R, Sausville EA, Stone MJ, StetlerStevenson MA, Uhr JW, Vitetta ES (1996) Decreases in levels of serum fibronectin predict the severity of vascular leak syndrome in patients treated with ricin A chain-containing immunotoxins. Clin Cancer Res 2(10):1705–1712
4. Borghaei H, Langer CJ, Millenson M, Ruth KJ, Litwin S, Tuttle H, Seldomridge JS, Rovito M, Mintzer D, Cohen R, Treat J (2008) Phase II study of paclitaxel, carboplatin, and cetuximab as first line treatment, for patients with advanced non-small cell lung cancer (NSCLC) results of OPN-017. J Thorac Oncol 3(11):1286–1292
5. Brekke OH, Sandlie I (2003) Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat Rev Drug Discov 2(1):52–62
Cited by
27 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献